Biogen Inc. and Eisai Co. Ltd. have begun rolling out their Alzheimer’s treatment Leqembi in the European Union, launching the drug in Austria today and scheduling its German debut for 1 September. The two countries are the first EU markets to offer the monoclonal antibody, which won European Commission clearance in April as the region’s inaugural therapy targeting an underlying cause of the disease. Leqembi is indicated for adults with early-stage Alzheimer’s who are apolipoprotein E ε4 non-carriers or heterozygotes with confirmed amyloid pathology. In the Phase 3 Clarity AD study, the medicine slowed clinical decline by 31 percent over 18 months compared with placebo, measured by the Clinical Dementia Rating–Sum of Boxes scale. Common side effects included infusion reactions and amyloid-related imaging abnormalities. Eisai leads global development and regulatory submissions, while the partners co-commercialize the drug in the EU under a controlled-access program designed to ensure safe use. The launches in Austria and Germany mark a critical step for Biogen and Eisai as they expand Leqembi’s footprint beyond the United States and other early-adopting markets.